128 related articles for article (PubMed ID: 24700598)
21. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*.
Hanrahan TP; Harlow G; Hutchinson J; Dulhunty JM; Lipman J; Whitehouse T; Roberts JA
Crit Care Med; 2014 Dec; 42(12):2527-36. PubMed ID: 25083977
[TBL] [Abstract][Full Text] [Related]
22. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
[TBL] [Abstract][Full Text] [Related]
23. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.
Luther MK; Timbrook TT; Caffrey AR; Dosa D; Lodise TP; LaPlante KL
Crit Care Med; 2018 Jan; 46(1):12-20. PubMed ID: 29088001
[TBL] [Abstract][Full Text] [Related]
24. The Nephrotoxicity of Vancomycin.
Filippone EJ; Kraft WK; Farber JL
Clin Pharmacol Ther; 2017 Sep; 102(3):459-469. PubMed ID: 28474732
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem.
Al Yami MS
J Infect Public Health; 2017; 10(6):770-773. PubMed ID: 28209320
[TBL] [Abstract][Full Text] [Related]
26. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?
Watkins RR; Deresinski S
Clin Infect Dis; 2017 Nov; 65(12):2137-2143. PubMed ID: 29020249
[TBL] [Abstract][Full Text] [Related]
27. Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility.
Anderson CW; Cazares KS; Lustik MB; Patel SM; Denunzio TM
Mil Med; 2017 Sep; 182(9):e1773-e1778. PubMed ID: 28885936
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with vancomycin nephrotoxicity in the critically ill.
Hanrahan TP; Kotapati C; Roberts MJ; Rowland J; Lipman J; Roberts JA; Udy A
Anaesth Intensive Care; 2015 Sep; 43(5):594-9. PubMed ID: 26310409
[TBL] [Abstract][Full Text] [Related]
29. Nephrotoxicity comparison of two commercially available generic vancomycin products.
Sutton JD; Mynatt RP; Kaye KS; Murray KP; Rybak MJ; Pogue JM
Antimicrob Agents Chemother; 2015 Sep; 59(9):5470-4. PubMed ID: 26124161
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for vancomycin nephrotoxicity: still a matter of debate*.
Costa e Silva VT; Marçal LJ; Burdmann EA
Crit Care Med; 2014 Dec; 42(12):2635-6. PubMed ID: 25402286
[No Abstract] [Full Text] [Related]
31. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity.
Rostas SE; Kubiak DW; Calderwood MS
Clin Ther; 2014 Jul; 36(7):1098-101. PubMed ID: 24931573
[TBL] [Abstract][Full Text] [Related]
32. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.
Hundeshagen G; Herndon DN; Capek KD; Branski LK; Voigt CD; Killion EA; Cambiaso-Daniel J; Sljivich M; De Crescenzo A; Mlcak RP; Kinsky MP; Finnerty CC; Norbury WB
Crit Care; 2017 Dec; 21(1):318. PubMed ID: 29262848
[TBL] [Abstract][Full Text] [Related]
33. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
[TBL] [Abstract][Full Text] [Related]
34. Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin-tazobactam.
Abouelkheir M; Alsubaie S
Pediatr Int; 2018 Feb; 60(2):136-141. PubMed ID: 29181890
[TBL] [Abstract][Full Text] [Related]
35. Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin.
Carreno JJ; Jaworski A; Kenney RM; Davis SL
Infect Dis Ther; 2013 Dec; 2(2):201-8. PubMed ID: 25134482
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y
Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
[TBL] [Abstract][Full Text] [Related]
37. Impact of a Pharmacist-Initiated Vancomycin Monitoring Program.
Smith AP; Millares-Sipin CA; James M; Cohen H
Consult Pharm; 2016 Sep; 31(9):505-10. PubMed ID: 27636875
[TBL] [Abstract][Full Text] [Related]
38. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
[TBL] [Abstract][Full Text] [Related]
39. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study.
Fralick M; Macdonald EM; Gomes T; Antoniou T; Hollands S; Mamdani MM; Juurlink DN;
BMJ; 2014 Oct; 349():g6196. PubMed ID: 25359996
[TBL] [Abstract][Full Text] [Related]
40. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies.
Barriere SL; Stryjewski ME; Corey GR; Genter FC; Rubinstein E
BMC Infect Dis; 2014 Apr; 14():183. PubMed ID: 24708675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
